CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS AND ANTIPSYCHOTIC‐INDUCED EXTRAPYRAMIDAL SIDE‐EFFECTS IN PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY
作者： Anna Crescenti , Sergi Mas , Patricia Gassó , Eduard Parellada , Miquel Bernardo
DOI: 10.1111/J.1440-1681.2008.04918.X
关键词:
摘要: 1. The aim of the present study was to examine relationship between CYP2D6 polymorphisms and risk antipsychotic (AP)-induced extrapyramidal symptoms (EPS) in patients receiving AP treatment. allele status for CYP2D6*3, CYP2D6*4, CYP2D6*5 CYP2D6*6 determined 267 therapy. Seventy-nine cases presenting with EPS (Simpson-Angus Scale 3) 188 controls without > took part study. 2. We found a non-significant over-representation poor metaboliser genotypes among cases, but significant association mutant homozygous genotype CYP2D6*4 (odds ratio (OR) 4.1, 95% confidence interval (CI) 1.01-16, permutated P value 0.01) heterozygous (OR 5.4, CI 1.13-18, 0.003) suffering EPS. 3. These results suggest that may be contributory factor development undergoing
sci-hub.se 参考文章(30)
Daniel E. Casey, Pathophysiology of antipsychotic drug-induced movement disorders. The Journal of Clinical Psychiatry. ,vol. 65, pp. 25- 28 ,(2004)
L. Laforest, H. Wikman, S. Benhamou, S.T. Saarikoski, C. Bouchardy, A. Hirvonen, P. Dayer, K. Husgafvel-Pursiainen, CYP2D6 gene polymorphism in Caucasian smokers European Journal of Cancer. ,vol. 36, pp. 1825- 1832 ,(2000) , 10.1016/S0959-8049(00)00185-4
C Sachse, S Bauer, J Brockmöller, I Roots, Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. American Journal of Human Genetics. ,vol. 60, pp. 284- 295 ,(1997)
U A Meyer, S Kimura, R C Skoda, F J Gonzalez, M Umeno, The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. American Journal of Human Genetics. ,vol. 45, pp. 889- 904 ,(1989)
Jakub Z. Konarski, Roger S. McIntyre, Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. The Journal of Clinical Psychiatry. ,vol. 66, pp. 28- 36 ,(2005)
Marja-Liisa Dahl, Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clinical Pharmacokinectics. ,vol. 41, pp. 453- 470 ,(2002) , 10.2165/00003088-200241070-00001
Maria Gabriella Scordo, Achille P Caputi, Concetta D’Arrigo, Giuseppina Fava, Edoardo Spina, Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacological Research. ,vol. 50, pp. 195- 200 ,(2004) , 10.1016/J.PHRS.2004.01.004
Daniel E. Casey, Extrapyramidal Syndromes CNS Drugs. ,vol. 5, pp. 1- 12 ,(1996) , 10.2165/00023210-199600051-00003
A Crescenti, S Mas, P Gassó, M Baiget, M Bernardo, A Lafuente, Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis. Clinical and Experimental Pharmacology and Physiology. ,vol. 34, pp. 992- 997 ,(2007) , 10.1111/J.1440-1681.2007.04665.X
Carl H. Miller, Fritz Mohr, Daniel Umbricht, Margaret Woerner, W. Wolfgang Fleischhacker, Jeffrey A. Lieberman, The Prevalence of Acute Extrapyramidal Signs and Symptoms in Patients Treated With Clozapine, Risperidone, and Conventional Antipsychotics The Journal of Clinical Psychiatry. ,vol. 59, pp. 69- 75 ,(1998) , 10.4088/JCP.V59N0205